News & Updates

A coordinated, multifaceted intervention of assessment, education, and feedback has resulted in an increase in the prescription of recommended, evidence-based therapies in adult patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (CVD), reveals a study presented at ACC 2023.

The use of menopausal hormone therapy (MHT), including the most prescribed agent tibolone, appears to contribute to an increase in the risk of type 2 diabetes mellitus (T2DM), as shown in a retrospective study.

One in six people with poorly controlled type 2 diabetes (T2D) in Singapore experiences diabetes distress, with the risk factors including younger age, previous tobacco use, kidney disease history, and depressive symptoms, as reported in a study.

Too much and too little consumption of phosphorus in the diet are deemed risky in relation to the likelihood of developing diabetes, with a study showing a U-shaped association between the phosphorous intake and new-onset diabetes.

Weight gain among adults appears to speed up a person’s biological age, with a recent study showing the associations of maximal overweight, nonobese to obese, and stable obesity across adulthood with accelerated biological ageing. On the other hand, weight loss from young to middle adulthood tends to slow down biological ageing.

Complement C3 levels may be used as a predictor of incident type 2 diabetes mellitus (T2DM), suggests a study. In addition, body mass index (BMI) may have a mediating role in the association between C3 and T2DM, offering clues for diabetes pathogenesis.

In a recent study, seliciclib therapy demonstrates its potential in reversing hypercortisolism by directly targeting pituitary corticotrophs in Cushing disease (CD). However, the agent is associated with liver toxicity, which is resolved by withdrawing treatment.